Shares of Kala Pharmaceuticals (KALA) fell to the mid-$13 range prior to Friday's rebound back above $15 on decent volume.
The company was not the usual speculative biotech firm tapping capital markets to progress an unproven, early-stage pipeline. They approached investors having already logged pivotal wins for their lead drug candidate and having a solid institutional backing.
MG+M The Law Firm (MG+M) is pleased to announce that it has elevated attorneys Stephanie M. Chesney
Burns & Levinson announced today that well-known plaintiff employment litigator Beth R. Myers has joined the firm
BayCoast Bank is delighted to announce Nicole Almeida as Senior Vice President, Chief Diversity Officer (CDO)
BayCoast Bank is pleased to announce Robert Bergdoll of Attleboro, Massachusetts, as First Vice President Marketing Director
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2024 citybuzz
